- Fee assured
- Verified this account
This healthcare professional let us know that they are currently:
- Accepting new patients
- Available for:
- Phone consultations
- Video consultations
- Face-to-face consultations
Last updated: 26 Jun 2020
Areas of interest
Polycystic ovarian syndrome
Transgender medicine - Hormone implant
Type 1 diabetes
Type 2 diabetes
Current NHS consultant posts held
Consultant Endocrinologist, Royal Sussex County Hospital
MRCP, PhD, FRCP
Ahmed FW, Rider R, Glanville M, Narayanan K, Razvi S and Weaver JW. Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT Study. Cardiovascular Diabetology. 2016; 15:116. DOI: 10.1186/s12933-016-0413-6.
Bakhashab S, Ahmed F, Schulten HJ, Ahmed FW, Glanville M, Al-Qahtani MH, Weaver JU. Proangiogenic effect of Metformin in endothelial cells is via upregulation of VEGFR1/2 and their signalling under hyperglycemia-hypoxia. Int J Mol Science; 2018:19 (1): doi: 10.3390/ijms19010293.
West DJ, Campbell MD, Gonzalez JT, Ahmed FW et al. The inflammation, vascular repair and injury responses to exercise in fit males with and without Type 1 diabetes: an observational study. Cardiovascular Diabetology. 2015;14:71. doi:10.1186/s12933-015-0235-y.
Bakhashab, S., Lary, S., Ahmed, F., Schulten, H.-J., Bashir, A., Ahmed, F. W., Weaver, J. U. (2014). Reference Genes for Expression Studies in Hypoxia and Hyperglycemia Models in Human Umbilical Vein Endothelial Cells.G3: Genes|Genomes|Genetics, 4(11), 2159–2165. doi:10.1534/g3.114.013102
Sennik D Ahmed FW and Russell JonesD. (2012) Exenatide, a GLP1 agonist in the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism. January 2012, Vol. 7, No. 1, Pages 1526, DOI 10.1586/eem.11.79
Ahmed FW, Ehsanullah U, Sennik D and RussellJones D (2011). Skin disorder in diabetic clinic Practical Diabetes. Volume 28 Issue 8. p 346-346
Ahmed FW and Sennik, D. (2011) Erythromycin Practical Diabetes. Volume 28 Issue 8. p 364-365a
Thong, K. Y., Ryder, R. E. J., Cull, M. L., Walton, C. and on behalf of the ABCD nationwide exenatide and liraglutide audit contributors (for list of contributors, see Supporting Information, Appendix S2) (2012), Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabetic Medicine, 29: 690–692. doi: 10.1111/j.1464-5491.2011.03475.x
Courses offered to GPs
Regular educational update to GP
Reference number 6068962
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.